| Entry |
|
|---|
| Name |
Sofosbuvir and velpatasvir;
Epclusa (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Component |
|
|---|
| Remark |
| Therapeutic category: | 6250 |
|
|---|
| Efficacy |
Antiviral |
|---|
| Disease |
Hepatitis C virus infection [DS: H00413] |
|---|
| Comment |
Sofosbuvir and Velpatasvir are substrates of BCRP and P-gp.
Velpatasvir is metabolized by CYP2B6, CYP2C8 and CYP3A4, and it is an inhibitor of the following transporters: P-gp, BCRP, OATP1B1 and OATP1B3.
|
|---|
| Target |
|
|---|
| Metabolism |
Enzyme: CYP2B6 [HSA: 1555], CYP2C8 [HSA: 1558], CYP3A4 [HSA: 1576]
Transporter: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429]
|
|---|
| Interaction |
Transporter inhibition: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429], SLCO1B1 [HSA: 10599], SLCO1B3 [HSA: 28234]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP55 Sofosbuvir and velpatasvir
D10827 Sofosbuvir and velpatasvir <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-hepatitis C (HCV) Agents
Velpatasvir/ Sofosbuvir
D10827 Sofosbuvir and velpatasvir
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D10827 Sofosbuvir and velpatasvir
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10827
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10827
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10827
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10827
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10827
Drug transporters
D10827
|
|---|
| Other DBs |
|
|---|
